Sage Therapeutics stock rockets 73% on hopes for breakthrough depression drug - MarketWatch
Sage surges after depression drug gets rapid path to approval - PMLiVE
Sage Therapeutics and Biogen pursue FDA approval for zuranolone
Sage Therapeutics Receives FDA Breakthrough Therapy Designation for SAGE-217 for the Treatment of Major Depressive Disorder - Chemdiv
Sage Therapeutics: Zuranolone's Multi-Billion Dollar Market Opportunity More Than Justifies Company Valuation (NASDAQ:SAGE) | Seeking Alpha
Deals In Depth: November 2020 :: Generics Bulletin
Discovering, developing and delivering life-changing therapies to treat rare central nervous system disorders.
sage-10k_20161231.htm
Breakthrough Agitation Agent; Demi Lovato's Bipolar Misdiagnosis? | MedPage Today
Sage Therapeutics Forges $575 Million Deal With Shionogi to Market Depression Drug in Parts of Asia | BioSpace
Sage Therapeutics Announces Promising Zuranolone Phase 3 Findings for Major Depression
Sage rethinks SAGE-217 program after phase 3 failure | Fierce Biotech
SY Investing on Twitter: "$SAGE (-62% PM) announced pivotal Ph 3 MOUNTAIN results of SAGE-217 in MDD. Study didn't meet primary endpoint. #Fail SAGE- 217 showed mean reduction of 12.6 in HAM-D total
Shionogi, Sage to Partner on Developing Depression Drug in Three Asian Markets
Sage advice: psychiatric drug development is tough | Evaluate
Sage Therapeutics' Deal With Biogen Should Revive It (NASDAQ:SAGE) | Seeking Alpha
Sage advice: psychiatric drug development is tough | Evaluate
On a Roll: FDA Calls Sage's Depression Drug a Breakthrough | BioSpace
BioWorld
GABA-A Agent SAGE-217: A New Antidepressant? - Gateway Psychiatric
Biogen and Sage Therapeutics Complete Rolling Submission of New Drug Application for Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression | Biogen
Sage Therapeutics Announces Development Plan for Zuranolone (SAGE-217) Following Breakthrough Therapy Guidance Meeting with the U.S. Food & Drug Administration | Business Wire
Sage Therapeutics and Biogen Initiate Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration for Zuranolone for the Potential Treatment of Major Depressive Disorder (MDD) | Business Wire
